Management increased full-year 2025 revenue guidance to $80M-100M, excluding ACT Genomics, up from the previous range of $73M-85M, demonstrating confidence in the core business trajectory.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRE:
- Prenetics to divest ACT Genomics to Delta Electronics in $71.78M transaction
- Prenetics Global Limited Appoints New Independent Director to Strengthen Bitcoin Strategy
- Prenetics Global Ltd trading resumes
- Prenetics Global Ltd trading halted, volatility trading pause
- Oracle reports Q4 beat, BioNTech to acquire CureVac: Morning Buzz